FOR 2 WEEKS leading up to the annual meeting of the American Society of Clinical Oncology (ASCO) last month, the media hoopla was intense surrounding 2 antiangiogenesis agents—compounds that inhibit the formation of new blood vessels, such as those that supply a cancerous tumor—that have shown potent anticancer activity in mice.
The frenzy of coverage in the nation's major newspapers, national news magazines, television, radio, and on the Internet led thousands of patients to besiege their physicians to help them obtain what some perceived as a cure for cancer.
Phillips P. Cancer Experts Offer Healthy Dose of Skepticism Toward Hype Over Antiangiogenesis Agents. JAMA. 1998;279(24):1936–1937. doi:10.1001/jama.279.24.1936-JMN0624-2-1